At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
LT3001 Drug Product +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Double-Blind, Single Dose, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Potential Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)
In Brief
A Phase 2 clinical trial evaluating LT3001 Drug Product and Placebo for Acute Ischemic Stroke. Completed, enrolled 24 participants across 10 sites in 2 countries.
Detailed Summary
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesTaiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartJan 2020
Primary CompletionFeb 2021
TodayJul 2026
First PostedSep 17, 2019
Enrollment StartJan 27, 2020
Primary CompletionFeb 22, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.8 years ago
Interventions
LT3001 Drug Productdrug
Active comparator
Placebodrug
Placebo comparator